grant
IL-1-based immunotherapy in HNSCC
Organization IOWA CITY VA MEDICAL CENTERLocation IOWA CITY, UNITED STATESPosted 1 Jan 2020Deadline 31 Mar 2030
VANIHUS FederalResearch GrantFY2025AccelerationAddressAdjuvantArteriesBeta Proprotein Interleukin 1BiodistributionBiologicalCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCancer PatientCell BodyCell Communication and SignalingCell LineCell MaturationCell SignalingCellLineCellsCheckpoint inhibitorClinicalClinical TrialsCo-cultureCocultivationCocultureCoculture TechniquesCytotoxic cellDataDendritic CellsDendritic cell activationDiagnosisDiseaseDisorderDistantDrug KineticsEffectivenessEncapsulatedEquilibriumFailureGeneral PopulationGeneral PublicHNSCCHead and Neck Squamous Cell CarcinomaHealth CareHealth StatusHexanesHypotensionIL-1IL-1 alphaIL-1 betaIL-1 βIL-1-aIL-1-bIL-1AIL-1alphaIL-1raIL-1αIL-1βIL1IL1 febrile inhibitorIL1-AlphaIL1-BetaIL1-αIL1-βIL1A ProteinIL1B ProteinIL1F1IL1F2IL1RNIL1βImmuneImmune Cell ActivationImmune checkpoint inhibitorImmune mediated therapyImmune responseImmunesImmunologically Directed TherapyImmunomodulationImmunotherapeutic agentImmunotherapyIn VitroInflammatory ResponseIntentionInterleukin 1alphaInterleukin 1betaInterleukin IInterleukin SuppressionInterleukin-1Interleukin-1 Receptor AntagonistInterleukin-1 alphaInterleukin-1 betaInterleukin-1βIntracellular Communication and SignalingK lymphocyteKineticsLevel of HealthLigandsLow Blood PressureLymphocyte-Stimulating HormoneMacrophage Cell FactorMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsMonitorMurineMusNK CellsNK T cellNKT cellNatural Killer CellsNatural Killer T cellNeoplasm MetastasisOperative ProceduresOperative Surgical ProceduresOutcomePBMCPD-1 antibodyPD1 antibodyPathway interactionsPatientsPeripheral Blood Mononuclear CellPharmacokineticsPhase 3 Clinical TrialsPhase III Clinical TrialsPlayPostoperativePostoperative PeriodPreinterleukin 1 AlphaPreinterleukin 1 BetaPrimary NeoplasmPrimary TumorPropertyProtocolProtocols documentationRadiation therapyRadiotherapeuticsRadiotherapyRandomizedRecombinant Interleukin-1RecurrenceRecurrentRecurrent diseaseRelapsed DiseaseReportingRiskRoleSCCHNSEER ProgramSEER-Surveillance, Epidemiology, and End ResultsSecondary NeoplasmSecondary TumorSignal TransductionSignal Transduction SystemsSignalingStrains Cell LinesSurgicalSurgical InterventionsSurgical ProcedureSurveillance, Epidemiology and End ResultsSurveillance, Epidemiology, and End Results ProgramT Helper FactorT-CellsT-LymphocyteT4 CellsT4 LymphocytesTargeted RadiotherapyTestingTimeToxic effectToxicitiesTranslationsTumor ImmunityTumor-Infiltrating LymphocytesTumor-infiltrating immune cellsVascular Hypotensive DisorderVeiled CellsVeteransaPD-1aPD1advanced diseaseadvanced illnessanakinraanti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor immune responseanti-tumor immunityantiPD-1antitumor immunitybalancebalance functionbiologicbiological signal transductioncancer immunitycancer metastasiscancer registrychemo-/radio-therapychemo-radiotherapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapychemotherapyco-morbidco-morbiditycomorbiditycontrolled releasecultured cell linecytokinecytotoxic CD8 T cellscytotoxic CD8 T lymphocytedecanedioic acidhead and neck squamous carcinomahead and neck squamous cell cancerhealth levelhigh riskhost responseimage guidanceimage guidedimmune activationimmune cell infiltration of tumorsimmune cells infiltrating the tumorimmune cells that infiltrate the tumorimmune check point inhibitorimmune drugsimmune modulationimmune regulationimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenicimmunologic reactivity controlimmunologic therapeuticsimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimmunotherapeuticsimmunotherapy agentimprovedin vivoinfiltration of tumors by immune cellsinnovateinnovationinnovativeinterleukin 1 receptor antagonist proteinintratumoral immune cellintratumoral immune infiltratelymphocyte activating factormanufacturemouse modelmurine modelnatural killer T lymphocyteneoplasm registrynew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachparticlepathwayphase III protocolpressurepreventpreventingradiation treatmentradio-chemo-therapyradio-chemotherapyradiochemotherapyrandomisationrandomizationrandomly assignedrecruitresponsesebacic acidside effectsocial rolestandard of caresurgerysurveillance datasurvival outcomethymus derived lymphocytetranslationtreatment with radiationtumortumor cell metastasistumor growthtumor immune celltumor immune infiltratetumor infiltration of immune cellsurine IL-1 inhibitorurine interleukin 1 inhibitorurine-derived IL1 inhibitorαPD-1αPD1
Description preview
Background and Innovation: The standard of care for locally advanced (LA) head and neck squamous cell
carcinoma (HNSCC) is surgery followed by post-operative radiotherapy (RT) or chemoradiotherapy (CRT).
Unfortunately, patients have a high risk of locoregional failure after RT and up to 50% of patients will develop
recurrent disease and/or second…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click